Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi AventisfiledCriticalSanofi Aventis
Priority to UY30441ApriorityCriticalpatent/UY30441A1/en
Publication of UY30441A1publicationCriticalpatent/UY30441A1/en
La invencion se refiere a compuestos de la formula I en la que R1, R2, ,X, A, B, Z e Y1 a Y4 tienen los significados indicados en las reivindicaciones, y/o una sal farmacéuticamente aceptable y/o un profármaco de los mismos. Debido a sus propiedades como inhibidores de receptores de quimioquinas, especialmente como inhibidores de CXCR2, los compuestos de la formula I y las sales farmacéuticamente aceptables y profármacos de los mismos son adecuados para la prevencion y tratamiento de enfermedades mediadas por quimioquinas.The invention relates to compounds of the formula I in which R1, R2,, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and / or a pharmaceutically acceptable salt and / or a prodrug of the same. Due to their properties as chemokine receptor inhibitors, especially as CXCR2 inhibitors, the compounds of formula I and pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine-mediated diseases.
UY30441A2007-06-262007-06-26
NEW CXCR2 INHIBITORS
UY30441A1
(en)